☆ 4.7 Article

Discovery of diaminotriazine carboxamides as potent inhibitors of hematopoetic progenitor kinase 1

BIOORGANIC CHEMISTRY (2023)

Related references

Note: Only part of the references are listed.

Article Biochemistry & Molecular Biology

The HPK1 Inhibitor A-745 Verifies the Potential of Modulating T Cell Kinase Signaling for Immunotherapy

Sven Malchow et al.

Summary: HPK1 is a member of the MAP4K family and plays a dominant role in negatively regulating T cell function, making it a potential target for immune therapy. The discovery of the selective and potent HPK1 chemical probe, A-745, demonstrates its ability to activate immune cells similar to HPK1-deficient T cells.

ACS CHEMICAL BIOLOGY (2022)

Add to Collection

Article Chemistry, Medicinal

Discovery of Spiro-azaindoline Inhibitors of Hematopoietic Progenitor Kinase 1 (HPK1)

Bryan K. Chan et al.

Summary: HPK1, identified as a negative regulator of T-cell activation, has potential implications in tumor therapy. Through structure-based drug design, a series of small molecule inhibitors of HPK1 were discovered with significantly improved kinase selectivity, showing potential therapeutic value in tumor treatment.

ACS MEDICINAL CHEMISTRY LETTERS (2022)

Add to Collection

Article Biochemical Research Methods

Development of High-Throughput Assays for Evaluation of Hematopoietic Progenitor Kinase 1 Inhibitors

Brian M. Lacey et al.

Summary: HPK1, a serine/threonine kinase, negatively regulates T-cell signaling and plays a crucial role in antitumor activity. A research team established various assays to identify high-affinity HPK1 inhibitors and successfully validated their effectiveness at the cellular level.

SLAS DISCOVERY (2021)

Add to Collection

Review Medicine, Research & Experimental

Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance

Sreya Bagchi et al.

Summary: This article highlights the significance of immune checkpoint inhibitors in cancer immunotherapy and the research findings on the changes in local and systemic immune cells after treatment. It emphasizes the need for understanding the requirements for an effective and safe antitumor immune response following ICI therapy.

ANNUAL REVIEW OF PATHOLOGY: MECHANISMS OF DISEASE, VOL 16, 2021 (2021)

Add to Collection

Article Biochemistry & Molecular Biology

Discovery of an Allosteric, Inactive Conformation-Selective Inhibitor of Full-Length HPK1 Utilizing a Kinase Cascade Assay

Weixue Wang et al.

Summary: Targeting inactive kinase conformations can lead to more selective kinase inhibitors. By applying cascade assays, a highly selective inhibitor for the cancer immunotherapy target kinase HPK1 was discovered, indicating the potential for further development of potent and selective inhibitors.

BIOCHEMISTRY (2021)

Add to Collection

Article Chemistry, Medicinal

Identification of Potent Reverse Indazole Inhibitors for HPK1

Elsie C. Yu et al.

Summary: The study optimized the structure of kinase inhibitor 4 through a systematic two-dimensional diversity screen of pyrazolopyridines, identifying potent and selective compounds. Further optimization led to the identification of potent and selective reverse indazole inhibitor 36 that exhibited low clearance and notable bioavailability in in vivo rat studies, inhibiting phosphorylation of adaptor protein SLP76 in human PBMC.

ACS MEDICINAL CHEMISTRY LETTERS (2021)

Add to Collection

Article Chemistry, Medicinal

Discovery of Orally Active Isofuranones as Potent, Selective Inhibitors of Hematopoetic Progenitor Kinase 1

Andrew P. Degnan et al.

Summary: The study presents a novel HPK1 inhibitor which, when used in combination in a colorectal cancer model, significantly enhances the efficacy of anti-PD1 treatment.

ACS MEDICINAL CHEMISTRY LETTERS (2021)

Add to Collection

Review Pharmacology & Pharmacy

RNA Dysregulation: An Expanding Source of Cancer Immunotherapy Targets

Yang Pan et al.

Summary: Recent advances in high-throughput technologies and rapid accumulation of multiomic cancer profiling data in public repositories have provided opportunities to systematically characterize RNA dysregulation in cancer and identify antigen targets for immunotherapy. However, important conceptual and technological challenges exist due to the complexity of cancer transcriptomes and proteomes.

TRENDS IN PHARMACOLOGICAL SCIENCES (2021)

Add to Collection

Article Chemistry, Medicinal

Discovery of Diaminopyrimidine Carboxamide HPK1 Inhibitors as Preclinical Immunotherapy Tool Compounds

Brandon A. Vara et al.

Summary: HPK1 is a negative immune regulator primarily expressed in hematopoietic cells, and its loss can enhance T cell signaling and cytokine production, leading to tumor growth inhibition in vivo. The structurally enabled discovery of novel, potent, and selective HPK1 inhibitors, with a carboxamide moiety crucial for enhanced potency and selectivity, holds promise as an immunotherapeutic target.

ACS MEDICINAL CHEMISTRY LETTERS (2021)

Add to Collection

Article Oncology

Hematopoietic Progenitor Kinase1 (HPK1) Mediates T Cell Dysfunction and Is a Druggable Target for T Cell-Based Immunotherapies

Jingwen Si et al.

CANCER CELL (2020)

Add to Collection

Article Multidisciplinary Sciences

Critical role of kinase activity of hematopoietic progenitor kinase 1 in anti-tumor immune surveillance

Jinqi Liu et al.

PLOS ONE (2019)

Add to Collection

Review Oncology

Next generation of immune checkpoint therapy in cancer: new developments and challenges

Julian A. Marin-Acevedo et al.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2018)

Add to Collection

Review Immunology

Combining immune Checkpoint inhibitors with Conventional Cancer Therapy

Yiyi Yan et al.

FRONTIERS IN IMMUNOLOGY (2018)

Add to Collection

Article Cell Biology

The Kinase Activity of Hematopoietic Progenitor Kinase 1 Is Essential for the Regulation of T Cell Function

Sairy Hernandez et al.

CELL REPORTS (2018)

Add to Collection

Review Oncology

De-novo and acquired resistance to immune checkpoint targeting

Nicholas L. Syn et al.

LANCET ONCOLOGY (2017)

Add to Collection

Review Biochemistry & Molecular Biology

Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy

Padmanee Sharma et al.

CELL (2017)

Add to Collection

Review Oncology

CTLA-4 and PD-1 Pathways Similarities, Differences, and Implications of Their Inhibition

Elizabeth I. Buchbinder et al.

AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2016)

Add to Collection

Review Chemistry, Medicinal

Cancer Immunotherapy: Selected Targets and Small-Molecule Modulators

Hilmar Weinmann

CHEMMEDCHEM (2016)

Add to Collection

Review Oncology

Acquired resistance to immunotherapy and future challenges

Nicholas P. Restifo et al.

NATURE REVIEWS CANCER (2016)

Add to Collection

Article Biotechnology & Applied Microbiology

Big opportunities for small molecules in immuno-oncology

Jerry L. Adams et al.

NATURE REVIEWS DRUG DISCOVERY (2015)

Add to Collection

Article Biochemistry & Molecular Biology

Attenuation of T Cell Receptor Signaling by Serine Phosphorylation-mediated Lysine 30 Ubiquitination of SLP-76 Protein

Xiaohong Wang et al.

JOURNAL OF BIOLOGICAL CHEMISTRY (2012)

Add to Collection

Article Cell Biology

Release of serine/threonine-phosphorylated adaptors from signaling microclusters down-regulates T cell activation

Remi Lasserre et al.

JOURNAL OF CELL BIOLOGY (2011)

Add to Collection

Article Oncology

Hematopoietic progenitor kinase 1 is a critical component of prostaglandin E2-mediated suppression of the anti-tumor immune response

Saba Alzabin et al.

CANCER IMMUNOLOGY IMMUNOTHERAPY (2010)

Add to Collection

Article Immunology

Hematopoietic Progenitor Kinase 1 Is a Negative Regulator of Dendritic Cell Activation

Saba Alzabin et al.

JOURNAL OF IMMUNOLOGY (2009)

Add to Collection

Article Immunology

Hematopoietic progenitor kinase 1 negatively regulates T cell receptor signaling and T cell-mediated immune responses

Jr-Wen Shui et al.

NATURE IMMUNOLOGY (2007)

Add to Collection

Article Biochemistry & Molecular Biology

Activation of hematopoietic progenitor kinase 1 involves relocation, autophosphorylation, and transphosphorylation by protein kinase D1

R Arnold et al.

MOLECULAR AND CELLULAR BIOLOGY (2005)

Add to Collection

Article Immunology

Essential role of the E3 ubiquitin ligase Cbl-b in T cell anergy induction

MS Jeon et al.

IMMUNITY (2004)

Add to Collection

Article Biochemistry & Molecular Biology

Involvement of hematopoietic progenitor kinase 1 in T cell receptor signaling

P Ling et al.

JOURNAL OF BIOLOGICAL CHEMISTRY (2001)

Add to Collection

Article Multidisciplinary Sciences

Negative regulation of lymphocyte activation and autoimmunity by the molecular adaptor Cbl-b

K Bachmaier et al.

NATURE (2000)

Add to Collection

© Peeref 2019-2024. All rights reserved.